Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) Phase 3 clinical trial of Gemcitabine and Cisplatin (GC) plus bevacizumab (B) or placebo (P)
- Citation:
- J Clin Oncol vol 40 (16_suppl) 4562-4562
- Meeting Instance:
- ASCO 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Parents:
- None
- Children:
- 4344
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U10CA180882, CA160312, U24CA196171
- Corr. Author:
- Authors:
- David J McConkey Woonyoung Choi Susan Halabi Bin Luo Hikmat Al-Ahmadie Jonathan E. Rosenberg Jack Mountain Ashley M. Regazzi Megan Fong Gopa Iyer Eli Van Allen Kent W. Mouw Yujia Wen Linda McCart Karla V. Ballman Misha Beltran Michael J. Morris
- Networks:
- LAPS-NY016
- Study
- CALGB-90601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: